Genetics and prescription opioid use (GaPO): study design for consenting a cohort from an existing biobank to identify clinical and genetic factors influencing prescription opioid use and abuse

• Published in: BMC medical genomics Vol. 14; no. 1; pp. 253 - 11
• Main Authors: Troiani, Vanessa, Crist, Richard C, Doyle, Glenn A, Ferraro, Thomas N, Beiler, Donielle, Ranck, Stephanie, McBryan, Kortney, Jarvis, Margaret A, Barbour, Jordan S, Han, John J, Ness, Ryan J, Berrettini, Wade H, Robishaw, Janet D
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26-10-2021; BioMed Central; BMC
• Subjects: Addiction; Addictions; Analgesics, Opioid - administration & dosage; Analgesics, Opioid - adverse effects; Anxiety; Behavior genetics; Biobanks; Biological Specimen Banks; Brain research; Chronic pain; Clinics; Consent; COVID-19; Drug abuse; Drug addiction; Drug use; Electronic Health Records; Electronic medical records; Genetic aspects; Genetic factors; Genetics; Genome-Wide Association Study; Genotyping; Health risk assessment; Humans; Medication abuse; Narcotics; Neuroimaging; Nicotine; Opioid use disorder (OUD); Opioid-Related Disorders - genetics; Opioids; Pain; Patients; Phenotypes; Prescriptions; Prospective Studies; Psychiatric research; Quality of life; Questionnaires; Recruitment; Risk factors; Study Protocol; Substance misuse; Web portals; United States; United States > US; Genetics; Addiction; Opioid use disorder (OUD); Substance misuse
• ISSN: 1755-8794; 1755-8794
• DOI: 10.1186/s12920-021-01100-z

Prescription opioids (POs) are commonly used to treat moderate to severe chronic pain in the health system setting. Although they improve quality of life for many patients, more work is needed to identify both the clinical and genetic factors that put certain individuals at high risk for developing opioid use disorder (OUD) following use of POs for pain relief. With a greater understanding of important risk factors, physicians will be better able to identify patients at highest risk for developing OUD for whom non-opioid alternative therapies and treatments should be considered.
We are conducting a prospective observational study that aims to identify the clinical and genetic factors most stongly associated with OUD. The study design leverages an existing biobank that includes whole exome sequencing and array genotyping. The biobank is maintained within an integrated health system, allowing for the large-scale capture and integration of genetic and non-genetic data. Participants are enrolled into the health system biobank via informed consent and then into a second study that focuses on opioid medication use. Data capture includes validated self-report surveys measuring addiction severity, depression, anxiety, and nicotine use, as well as additional clinical, prescription, and brain imaging data extracted from electronic health records.
We will harness this multimodal data capture to establish meaningful patient phenotypes in order to understand the genetic and non-genetic contributions to OUD.